Ligand Pharmaceuticals (NASDAQ:LGND) Director Martine Zimmermann Sells 2,000 Shares of Stock

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) Director Martine Zimmermann sold 2,000 shares of the company’s stock in a transaction dated Thursday, November 12th. The shares were sold at an average price of $318.17, for a total value of $636,340.00. Following the completion of the sale, the director owned 1,782 shares in the company, valued at $566,978.94. This trade represents a 52.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Martine Zimmermann also recently made the following trade(s):

  • On Thursday, September 10th, Martine Zimmermann sold 1,200 shares of Ligand Pharmaceuticals stock. The stock was sold at an average price of $285.00, for a total value of $342,000.00.

Ligand Pharmaceuticals Trading Down 2.3%

Shares of Ligand Pharmaceuticals stock traded down $7.08 during midday trading on Monday, reaching $301.71. The company had a trading volume of 186,903 shares, compared to its average volume of 263,991. The stock has a fifty day moving average price of $301.71 and a 200 day moving average price of $258.02. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.22 and a quick ratio of 1.19. The firm has a market cap of $6.04 billion, a PE ratio of 134.69, a P/E/G ratio of 5.39 and a beta of 1.16. Ligand Pharmaceuticals Incorporated has a fifty-two week low of $175.89 and a fifty-two week high of $326.63.

Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) last announced its earnings results on Thursday, October 29th. The biotechnology company reported $2.67 EPS for the quarter, beating the consensus estimate of $2.33 by $0.34. The business had revenue of $78.75 million for the quarter, compared to analysts’ expectations of $77.00 million. Ligand Pharmaceuticals had a return on equity of 5.22% and a net margin of 20.27%. The firm’s revenue was down 31.8% on a year-over-year basis. During the same period in the prior year, the business posted $3.09 earnings per share. On average, equities analysts anticipate that Ligand Pharmaceuticals Incorporated will post 2.35 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on LGND. Royal Bank Of Canada boosted their target price on shares of Ligand Pharmaceuticals from $345.00 to $357.00 and gave the company an “outperform” rating in a research report on Friday, October 30th. Barclays raised their price target on shares of Ligand Pharmaceuticals from $345.00 to $350.00 and gave the stock an “overweight” rating in a report on Wednesday, November 11th. Oppenheimer restated an “outperform” rating and issued a $326.00 price target (up from $285.00) on shares of Ligand Pharmaceuticals in a report on Monday, August 3rd. Leerink Partners assumed coverage on shares of Ligand Pharmaceuticals in a research note on Friday, August 14th. They issued an “outperform” rating and a $330.00 price target for the company. Finally, Citigroup upped their price objective on shares of Ligand Pharmaceuticals from $397.00 to $402.00 and gave the company a “buy” rating in a report on Thursday, November 5th. Eight research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $355.38.

View Our Latest Stock Analysis on Ligand Pharmaceuticals

Institutional Investors Weigh In On Ligand Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Janus Henderson Group PLC increased its holdings in Ligand Pharmaceuticals by 1.5% during the 1st quarter. Janus Henderson Group PLC now owns 1,009,891 shares of the biotechnology company’s stock worth $201,623,000 after purchasing an additional 14,491 shares in the last quarter. Rice Hall James & Associates LLC lifted its holdings in shares of Ligand Pharmaceuticals by 1.4% in the first quarter. Rice Hall James & Associates LLC now owns 283,567 shares of the biotechnology company’s stock valued at $56,614,000 after purchasing an additional 3,940 shares in the last quarter. Ranger Investment Management L.P. bought a new position in shares of Ligand Pharmaceuticals in the second quarter valued at approximately $81,424,000. Russell Investments Group Ltd. lifted its holdings in shares of Ligand Pharmaceuticals by 41.4% in the third quarter. Russell Investments Group Ltd. now owns 170,089 shares of the biotechnology company’s stock valued at $53,131,000 after purchasing an additional 49,785 shares in the last quarter. Finally, Bank of America Corp DE boosted its position in shares of Ligand Pharmaceuticals by 31.4% during the first quarter. Bank of America Corp DE now owns 157,865 shares of the biotechnology company’s stock valued at $31,518,000 after buying an additional 37,696 shares during the last quarter. Institutional investors and hedge funds own 91.28% of the company’s stock.

Ligand Pharmaceuticals Company Profile

(Get Free Report)

Ligand Pharmaceuticals is a biopharmaceutical company that works with pharmaceutical and biotechnology partners to develop and commercialize medicines. Rather than focusing primarily on selling drugs directly, Ligand licenses technologies and drug-development assets and may receive royalties and other payments from partner programs. Its technologies include Captisol, a formulation platform designed to improve the solubility and delivery of certain medicines. Ligand also holds economic interests in a portfolio of partnered products and drug candidates across multiple therapeutic areas.

Further Reading

Insider Buying and Selling by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)

Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.